Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma

Valerie B. Sampson, Nancy S. Vetter, Wendong Zhang, Pratima U. Patil, Robert W. Mason, Erika George, Richard Gorlick, Edward A. Kolb

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Osteosarcoma is the most frequently occurring bone cancer in children and adolescents. Unfortunately, treatment failures are common. Eribulin is a synthetic microtubule inhibitor that has demonstrated activity in preclinical osteosarcoma models. The effects of eribulin were evaluated in two human osteosarcoma cell lines as well as in eribulin-sensitive and -resistant osteosarcoma xenograft tumors of the Pediatric Preclinical Testing Program (PPTP) by characterizing cell viability, microtubule destabilization, mitotic arrest and mechanism of cell death. Eribulin demonstrated cytotoxic activity in vitro, through promotion of microtubule dynamic instability, arrest of cells in the G2/M phase, mitotic catastrophe and cell death. The microtubuledestabilizing protein stathmin-1 (STMN1) was coimmunoprecipitated with the cyclindependent kinase inhibitor p27 indicating that these cytoplasmic complexes can protect cells from the microtubule destabilizing effect of eribulin. Increased tumoral expression of P-glycoprotein (P-gp) and TUBB3 were also associated with lower drug sensitivity. In summary, eribulin successfully blocked cells in G2/M phase but interfered with mitochondria activity to inhibit proteins involved in apoptosis. Understanding the complex and inter-related mechanisms involved in the overall drug response to eribulin may help in the design of therapeutic strategies that enhance drug activity and improve benefits of eribulin in pediatric patients with osteosarcoma.

Original languageEnglish (US)
Pages (from-to)86594-86607
Number of pages14
JournalOncotarget
Volume7
Issue number52
StatePublished - 2016

Fingerprint

eribulin
Osteosarcoma
Tubulin
Microtubules
G2 Phase
Cell Division
Cell Death
Stathmin
Pharmaceutical Preparations
Pediatrics
Bone Neoplasms
P-Glycoprotein
Treatment Failure
Heterografts

Keywords

  • Cell death
  • Eribulin
  • G2/M arrest
  • Microtubule destabilization
  • Mitotic catastrophe

ASJC Scopus subject areas

  • Oncology

Cite this

Sampson, V. B., Vetter, N. S., Zhang, W., Patil, P. U., Mason, R. W., George, E., ... Kolb, E. A. (2016). Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma. Oncotarget, 7(52), 86594-86607.

Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma. / Sampson, Valerie B.; Vetter, Nancy S.; Zhang, Wendong; Patil, Pratima U.; Mason, Robert W.; George, Erika; Gorlick, Richard; Kolb, Edward A.

In: Oncotarget, Vol. 7, No. 52, 2016, p. 86594-86607.

Research output: Contribution to journalArticle

Sampson, VB, Vetter, NS, Zhang, W, Patil, PU, Mason, RW, George, E, Gorlick, R & Kolb, EA 2016, 'Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma', Oncotarget, vol. 7, no. 52, pp. 86594-86607.
Sampson VB, Vetter NS, Zhang W, Patil PU, Mason RW, George E et al. Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma. Oncotarget. 2016;7(52):86594-86607.
Sampson, Valerie B. ; Vetter, Nancy S. ; Zhang, Wendong ; Patil, Pratima U. ; Mason, Robert W. ; George, Erika ; Gorlick, Richard ; Kolb, Edward A. / Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma. In: Oncotarget. 2016 ; Vol. 7, No. 52. pp. 86594-86607.
@article{6c757910c42b45429c34f6db6132b245,
title = "Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma",
abstract = "Osteosarcoma is the most frequently occurring bone cancer in children and adolescents. Unfortunately, treatment failures are common. Eribulin is a synthetic microtubule inhibitor that has demonstrated activity in preclinical osteosarcoma models. The effects of eribulin were evaluated in two human osteosarcoma cell lines as well as in eribulin-sensitive and -resistant osteosarcoma xenograft tumors of the Pediatric Preclinical Testing Program (PPTP) by characterizing cell viability, microtubule destabilization, mitotic arrest and mechanism of cell death. Eribulin demonstrated cytotoxic activity in vitro, through promotion of microtubule dynamic instability, arrest of cells in the G2/M phase, mitotic catastrophe and cell death. The microtubuledestabilizing protein stathmin-1 (STMN1) was coimmunoprecipitated with the cyclindependent kinase inhibitor p27 indicating that these cytoplasmic complexes can protect cells from the microtubule destabilizing effect of eribulin. Increased tumoral expression of P-glycoprotein (P-gp) and TUBB3 were also associated with lower drug sensitivity. In summary, eribulin successfully blocked cells in G2/M phase but interfered with mitochondria activity to inhibit proteins involved in apoptosis. Understanding the complex and inter-related mechanisms involved in the overall drug response to eribulin may help in the design of therapeutic strategies that enhance drug activity and improve benefits of eribulin in pediatric patients with osteosarcoma.",
keywords = "Cell death, Eribulin, G2/M arrest, Microtubule destabilization, Mitotic catastrophe",
author = "Sampson, {Valerie B.} and Vetter, {Nancy S.} and Wendong Zhang and Patil, {Pratima U.} and Mason, {Robert W.} and Erika George and Richard Gorlick and Kolb, {Edward A.}",
year = "2016",
language = "English (US)",
volume = "7",
pages = "86594--86607",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "52",

}

TY - JOUR

T1 - Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma

AU - Sampson, Valerie B.

AU - Vetter, Nancy S.

AU - Zhang, Wendong

AU - Patil, Pratima U.

AU - Mason, Robert W.

AU - George, Erika

AU - Gorlick, Richard

AU - Kolb, Edward A.

PY - 2016

Y1 - 2016

N2 - Osteosarcoma is the most frequently occurring bone cancer in children and adolescents. Unfortunately, treatment failures are common. Eribulin is a synthetic microtubule inhibitor that has demonstrated activity in preclinical osteosarcoma models. The effects of eribulin were evaluated in two human osteosarcoma cell lines as well as in eribulin-sensitive and -resistant osteosarcoma xenograft tumors of the Pediatric Preclinical Testing Program (PPTP) by characterizing cell viability, microtubule destabilization, mitotic arrest and mechanism of cell death. Eribulin demonstrated cytotoxic activity in vitro, through promotion of microtubule dynamic instability, arrest of cells in the G2/M phase, mitotic catastrophe and cell death. The microtubuledestabilizing protein stathmin-1 (STMN1) was coimmunoprecipitated with the cyclindependent kinase inhibitor p27 indicating that these cytoplasmic complexes can protect cells from the microtubule destabilizing effect of eribulin. Increased tumoral expression of P-glycoprotein (P-gp) and TUBB3 were also associated with lower drug sensitivity. In summary, eribulin successfully blocked cells in G2/M phase but interfered with mitochondria activity to inhibit proteins involved in apoptosis. Understanding the complex and inter-related mechanisms involved in the overall drug response to eribulin may help in the design of therapeutic strategies that enhance drug activity and improve benefits of eribulin in pediatric patients with osteosarcoma.

AB - Osteosarcoma is the most frequently occurring bone cancer in children and adolescents. Unfortunately, treatment failures are common. Eribulin is a synthetic microtubule inhibitor that has demonstrated activity in preclinical osteosarcoma models. The effects of eribulin were evaluated in two human osteosarcoma cell lines as well as in eribulin-sensitive and -resistant osteosarcoma xenograft tumors of the Pediatric Preclinical Testing Program (PPTP) by characterizing cell viability, microtubule destabilization, mitotic arrest and mechanism of cell death. Eribulin demonstrated cytotoxic activity in vitro, through promotion of microtubule dynamic instability, arrest of cells in the G2/M phase, mitotic catastrophe and cell death. The microtubuledestabilizing protein stathmin-1 (STMN1) was coimmunoprecipitated with the cyclindependent kinase inhibitor p27 indicating that these cytoplasmic complexes can protect cells from the microtubule destabilizing effect of eribulin. Increased tumoral expression of P-glycoprotein (P-gp) and TUBB3 were also associated with lower drug sensitivity. In summary, eribulin successfully blocked cells in G2/M phase but interfered with mitochondria activity to inhibit proteins involved in apoptosis. Understanding the complex and inter-related mechanisms involved in the overall drug response to eribulin may help in the design of therapeutic strategies that enhance drug activity and improve benefits of eribulin in pediatric patients with osteosarcoma.

KW - Cell death

KW - Eribulin

KW - G2/M arrest

KW - Microtubule destabilization

KW - Mitotic catastrophe

UR - http://www.scopus.com/inward/record.url?scp=85007496309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007496309&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85007496309

VL - 7

SP - 86594

EP - 86607

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 52

ER -